The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant interest within the United Kingdom , prompting a notable shift in peptide trends. Access these compounds remains a complex situation , with NHS coverage currently limited and independent providers offering therapy at a premium . Concerns are being raised reg